COMPANY
Gryphon Bio Inc.
Funding and NIH signals
- NIH award NIH awarded $1.25M (SBIR Phase II 5R44NS130780-03, continuation, notice Aug 24, 2026). NIH RePORTER 5R44NS130780-03 (Aug 24, 2026)
Evidence (1 event)
- Aug 24, 2026 · NIH RePORTER 5R44NS130780-03
Organization: GRYPHON BIO, INC.; City/State: SOUTH SAN FRANCISCO, CA; Project number: 5R44NS130780-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 1246138; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of Novel sgp130-Fc Bioconjugates for TBI; Organization type: Domestic For-Profits
- Aug 24, 2026 · NIH RePORTER 5R44NS130780-03
Timeline
- Grant Government grant — SBIR: $1.25M (annual award, as published), announced Aug 24, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
- Grant Government grant — SBIR: $1.24M (annual award, as published), announced Sep 13, 2025. Agency: NIH/NINDS. Source: government award database. source ↗
Funding
NIH awards 2
- NIH award 1R44NS130780-01 FY2023: $484,997 awarded for that fiscal year; activity R44 (SBIR); PI HASKINS, WILLIAM E; recipient as written: GRYPHON BIO, INC., SOUTH SAN FRANCISCO, CA. Development of Novel sgp130-Fc Bi source ↗
- NIH award 1R44NS117221-01A1 FY2021: $499,065 awarded for that fiscal year; activity R44 (SBIR); PI HASKINS, WILLIAM E; recipient as written: GRYPHON BIO, INC., SOUTH SAN FRANCISCO, CA. Temporal Biomarker-Powered Immu source ↗